Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Dianthus Therapeutics, Inc. - Common Stock (NQ: DNTH )

29.06 -0.84 (-2.81%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 168,296
Open 32.25
Bid (Size) 26.71 (5)
Ask (Size) 31.70 (1)
Prev. Close 29.90
Today's Range 28.27 - 32.27
52wk Range 6.580 - 33.77
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
A Glimpse Into The Expert Outlook On Dianthus Therapeutics Through 4 Analysts
Via Benzinga
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results
From Dianthus Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+153.80%
+153.80%
1 Month
+3.82%
+3.82%
3 Month
+8.68%
+8.68%
6 Month
+16.57%
+16.57%
1 Year
+155.58%
+155.58%

More News

Read More
Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Expert Ratings For Dianthus Therapeutics
Via Benzinga
Navigating 4 Analyst Ratings For Dianthus Therapeutics
Via Benzinga
Dianthus Therapeutics to Participate in Three Healthcare Investor Conferences in September
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Ulta Beauty Reports Downbeat Results, Joins Elastic And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
DNTH Stock Earnings: Dianthus Therapeutics Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
What 5 Analyst Ratings Have To Say About Dianthus Therapeutics
Via Benzinga
What 5 Analyst Ratings Have To Say About Dianthus Therapeutics
Via Benzinga
Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN)
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Dianthus Therapeutics Announces FDA Clearance to Initiate Phase 2 Trial of DNTH103 in Multifocal Motor Neuropathy (MMN)
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Dianthus Therapeutics to Participate in the Jefferies Global Healthcare Conference
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
DNTH Stock Earnings: Dianthus Therapeutics Misses EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Dianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care Conference
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Dianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual Meeting
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Why Cutera Shares Are Trading Lower By Over 26%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Worthington Steel Posts Upbeat Results, Joins Summit Midstream Partners, FedEx And Other Big Stocks Moving Higher On Friday
Via Benzinga
Topics Stocks
Exposures US Equities
DNTH Stock Earnings: Dianthus Therapeutics Beats EPS, Beats Revenue for Q4 2023
Via InvestorPlace
Dianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.